Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35583| Title: | Management of patients with follicular lymphoma treated first line with obinutuzumab. | Authors: | Opat S. ;Trotman J.;Thorburn A.N.;Boulos J.;Tam C.;Cheah C.Y.;Dickinson M. | Institution: | (Opat) School of Clinical Sciences, Monash Health, Monash University, Clayton, Melbourne, VIC, Australia (Dickinson, Tam) Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia (Tam) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Boulos, Thorburn) Roche Products Pty Ltd, Sydney, NSW, Australia (Trotman) Haematology Department, Concord Hospital, University of Sydney, Concord, NSW, Australia | Issue Date: | 15-May-2019 | Copyright year: | 2019 | Publisher: | Blackwell Publishing Ltd | Place of publication: | United Kingdom | Publication information: | Asia-Pacific Journal of Clinical Oncology. 15 (S3) (pp 3-11), 2019. Date of Publication: May 2019. | Journal: | Asia-Pacific Journal of Clinical Oncology | Abstract: | Recently, obinutuzumab was included in the Australian Pharmaceutical Benefits Scheme for use in first line, advanced or bulky stage 2, follicular lymphoma, providing more immunochemotherapy treatment options available than ever before. Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade >=3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.Copyright © 2019 John Wiley & Sons Australia, Ltd | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajco.13153 | PubMed URL: | 31058467 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31058467] | ISSN: | 1743-7555 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35583 | Type: | Article | Subjects: | practice guideline priority journal thrombocytopenia/pc [Prevention] thrombocytopenia/si [Side Effect] time to treatment tumor lysis syndrome/pc [Prevention] tumor lysis syndrome/si [Side Effect] *obinutuzumab/ae [Adverse Drug Reaction] *obinutuzumab/dt [Drug Therapy] infusion related reaction/si [Side Effect] article Australia bleeding/pc [Prevention] bleeding/si [Side Effect] cancer chemotherapy cancer growth cancer recurrence drug use *follicular lymphoma/dt [Drug Therapy] human incidence infection/pc [Prevention] infection/si [Side Effect] infusion related reaction/pc [Prevention] maintenance therapy medical decision making minimal residual disease neutropenia/si [Side Effect] positron emission tomography infusion related reaction / prevention / side effect maintenance therapy medical decision making minimal residual disease neutropenia / side effect positron emission tomography practice guideline priority journal thrombocytopenia / prevention / side effect bleeding / prevention / side effect tumor lysis syndrome / prevention / side effect Australia Article time to treatment cancer chemotherapy cancer growth cancer recurrence drug use *follicular lymphoma / *drug therapy human incidence infection / prevention / side effect |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.